In after-hours trading on Thursday, Accelerate Diagnostics Inc. (AXDX) rose 10.69% at $7.25. During the last trading session, Accelerate Diagnostics stock lost -2.38% to finish at $6.55. During the day, AXDX was trading between $6.50 and $6.79. There were 0.15 million shares traded on AXDX stock, lower than its daily average of 0.21 million shares over 100 days.

Over the last five days, shares of AXDX fell by -8.90%, while overall, they declined by -27.14% during the past month. As a consequence of the announcement of its conference call date to discuss quarterly results, AXDX stock gained traction.

When will ACDX release its results?

Dedicated to providing solutions to the global challenges of sepsis and antibiotic resistance, Accelerate Diagnostics is a leading in vitro diagnostics company. As part of AXDX’s Accelerate Pheno system and Accelerate PhenoTest BC kit, clinicians are able to determine the most appropriate antibiotic therapy for serious infections more quickly.

In about 7 hours directly from a positive blood culture, AXDX’s FDA-cleared system and kit automate sample preparation steps to provide phenotypic susceptibility results for antibiotics. The AXDX solution provides results one to two days faster than existing methods, enabling clinicians to optimize antibiotic selection and dosage based on the patient’s infection.

An Accelerate Diagnostics conference call will be held at 4:30pm Eastern Time on Thursday, August 5, 2021. AXDX will review the financial results for the second quarter of 2021.

Investors can listen to the audio webcast online by visiting the AXDX website. AXDX will make the audio webcast replay available through November 5, 2021.

Added to its Accelerate PhenoTest BC kit is a new IVD configuration launched by Accelerate Diagnostics recently in the United States.

• AXDX is now offering two solutions for rapid sepsis testing.
• A fast and flexible solution for laboratories who already have rapid identification systems, the new configuration provides fast antimicrobial susceptibility testing (AST) results from positive blood cultures in approximately 7 hours.
• As a result, labs needing both fast identification and fast AST now have an integrated solution with AXDX’s FDA-cleared Accelerate PhenoTest BC kit, which includes an ID/AST configuration.
• Rapid improvements in clinical outcomes have been demonstrated with the Accelerate Pheno system, including faster time to results, a shorter therapy duration, and a shorter hospital stay.

How this expansion will benefit AXDX?

Accelerate Diagnostics (AXDX)’s rapid susceptibility testing product expansion will give customers new access to our proven benefits. Generally, market feedback has been positive, especially from customers who already have rapid identification systems, but still need susceptibility results as soon as possible to support patients in getting the right treatment. AST configuration will drive sales funnels, Pheno placements, and future revenues for AXDX based on the strong interest from customers as well as improved access.